Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular risk

Eric P. Brass, William R. Hiatt, Raymond J. Lipicky et al.|Clinical Pharmacology & Therapeutics|2006

Cited by 22